Comparison of plasma exchange performances between Spectra Optia and COBE Spectra apheresis systems in repeated procedures considering variability and using specific statistical models

O Hequet; V Stocco; S Assari; P Drillat; Q H Le; A Kassir; D Rigal; R Bouzgarrou

doi:10.1016/j.transci.2014.07.005

Comparison of plasma exchange performances between Spectra Optia and COBE Spectra apheresis systems in repeated procedures considering variability and using specific statistical models

Transfus Apher Sci. 2014 Aug;51(1):47-53. doi: 10.1016/j.transci.2014.07.005. Epub 2014 Jul 28.

Authors

O Hequet¹, V Stocco², S Assari³, P Drillat³, Q H Le⁴, A Kassir⁵, D Rigal⁵, R Bouzgarrou⁶

Affiliations

¹ Etablissement Français du Sang Rhône-Alpes, Apheresis Unit, Pierre Bénite, France. Electronic address: olivier.hequet@efs.sante.fr.
² Etablissement Français du Sang Pays de Loire, Apheresis Unit, Nantes, France.
³ Department of Medical Direction, Etablissement Français du Sang, St Denis, France.
⁴ Department of Biostatistics, Hospices Civils de Lyon, Pierre Bénite, France.
⁵ Etablissement Français du Sang Rhône-Alpes, Apheresis Unit, Pierre Bénite, France.
⁶ Etablissement Français du Sang, Apheresis Unit, Bordeaux, France.

PMID: 25130725
DOI: 10.1016/j.transci.2014.07.005

Abstract

Repeated therapeutic plasma exchange (TPE) procedures using centrifugation techniques became a standard therapy in some diseases. As the new device Spectra Optia (SPO; Terumo BCT) was available, we studied its performances in repeated procedures in 20 patients in three apheresis units. First we analysed the performance results obtained by SPO. Second we compared the performances of the SPO device to a standard device, COBE Spectra (CSP; Terumo BCT) in the same patients using statistical method of mixed effects linear regression that considers variability between patients, centres and apheresis procedures. The performances analysed were classified according to plasma removal performances and their consequences on patients whose blood disturbances were assessed. Primary outcome was plasma removal efficiency (PRE) and PRE-anticoagulant corrected which was a more accurate parameter. Secondary outcomes corresponded to the volume of ACD-A consumed, platelets content in waste bag, procedure duration and status of coagulation system observed after TPE sessions. Before comparing the performances of both devices we compared the plasma volumes (PVs) processed in both techniques which showed that the PVs processed in SPO procedures were lower than in CSP procedures. In these conditions the statistical analysis revealed similar performances in both apheresis devices in PRE (p = ns) but better performances with SPO when considering higher PRE corrected by anticoagulant volume used (p < 0.05). Comparison of secondary outcomes showed no difference after SPO and CSP. After verifying that pre-apheresis patients' coagulation blood levels were identical before SPO and CSP, we showed identical haemostasis disturbances after SPO and CSP but lower platelet losses and higher fibrinogen post-apheresis blood levels after SPO (p < 0.05). No side effects or technical complications occurred during and after SPO and CSP. This study demonstrated that the Spectra Optia device is an alternative device to today's standard, the COBE Spectra device.

Keywords: Evaluation; Performances; Plasma exchange; Spectra Optia.

Publication types

Comparative Study

MeSH terms

Adult
Blood Component Removal / instrumentation*
Blood Component Removal / methods
Female
Humans
Male
Models, Statistical*
Plasma Exchange / instrumentation*
Plasma Exchange / methods
Prospective Studies